Using lab tumor markers to predict colorectal cancer recurrence
Part of Cancer, Digestive system clinical trials.
This study looks at tumor test results and medical history to estimate your risk of the cancer coming back or spreading after early-stage colorectal cancer surgery. It may help doctors predict who needs closer follow-up in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early colorectal cancer: stage I or II (T1–4, N0, M0)
- Your colon cancer was treated with surgery to fully remove it (radical resection)
- You have tumor tissue available, plus test results for either MSI or IHC
- Your records must include BRAF, KRAS, and CIMP test results from tumor testing
- You have at least 4 years of follow-up, including time to local recurrence or metastasis
- Your records must include surgery and pre-surgery details, like intestinal obstruction or perforation status, and lymph nodes removed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a blood test (liquid biopsy) to look for tiny bits of cancer DNA remaining after surgery. It aims to see if this test can help guide follow-up and treatment decisions for people with colorectal cancer.
This trial checks a blood test for “ctDNA methylation” to see who may be at higher risk of colorectal cancer returning after surgery. It may help doctors better judge whether adjuvant chemotherapy is working or needed.
This study tests if a simple blood test can detect early signs of colorectal cancer coming back after surgery to remove cancer spread in the abdomen. It may help patients avoid unnecessary treatments and catch recurrence sooner.
This study looks at whether a combination of clinical factors and genetic tests can better predict early return of cancer in people who had surgery for colorectal cancer that spread to the liver. It may help guide future treatment decisions.
This trial uses a blood test to track changes in cancer-related DNA markers (methylation) to see how well treatment is working. It is for people with colorectal or small intestinal cancer that has not spread and who have not yet started treatment.
This study checks a special blood test (circulating tumor DNA methylation) to help guide follow-up after surgery for non-metastatic colon cancer. It may help find whether additional treatment or closer monitoring is needed based on the test results.
Hear when a new Colorectal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.